by National Cancer Institute A drug that is designed to boost the immune system against mesothelioma, when combined with immunotherapy, was found to be beneficial in a small study involving ten patients. The results, which appeared July 1, 2020, in Science Translational Medicine, suggest that the drug LMB-100 could prolong the life of some patients...
Tag: <span>Pembrolizumab</span>
Immunotherapy for bowel cancer could change clinical practice
A large international trial involving UCL and University College London Hospitals NHS Foundation Trust (UCLH) has found that pembrolizumab, a form of immunotherapy, more than doubled the ‘progression free survival’ time of patients with a specific subtype of advanced bowel cancer, when compared with chemotherapy. ‘Progression free survival’ is the length of time during and...
Interleukin-12 electroporation may sensitize ‘cold’ melanomas to immunotherapies
by American Association for Cancer Research Combining intratumoral electroporation of interleukin-12 (IL-12) DNA (tavokinogene telseplasmid, or TAVO) with the immune checkpoint inhibitor pembrolizumab (Keytruda) led to clinical responses in patients with immunologically quiescent advanced melanoma, according to results from a phase II trial published in Clinical Cancer Research, a journal of the American Association for...
Combination approach shows promise for beating advanced melanoma
In UCLA-led study, new treatment is more effective in people receiving immunotherapy for the first time UNIVERSITY OF CALIFORNIA – LOS ANGELES HEALTH SCIENCES A UCLA-led study has found that a treatment that uses a bacteria-like agent in combination with an immunotherapy drug could help some people with advanced melanoma, an aggressive form of skin...
The immunotherapy, pembrolizumab, is active against mucosal melanoma tumors
And prolongs survival for patients with bladder cancer Amsterdam, The Netherlands: Clinical trials of a new immunotherapy, pembrolizumab, have shown that it prolongs life significantly for patients with bladder cancer and is active against a rare sub-type of melanoma, called mucosal melanoma. The findings were presented in two presentations at the European Cancer Congress 2017...